Funding for this research was provided by:
Cancer Research UK (C543/A26884, C543/A26884)
Article History
Received: 2 October 2020
Revised: 15 February 2021
Accepted: 24 February 2021
First Online: 26 March 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Not applicable.
: F.J.G. receives research support from Hologic, GE Healthcare, Bayer, Volpara. F.J.G. has research collaborations with Merantix, Screen-Point, Lunit. F.J.G. undertakes consultancy for DeepMind/Alphabet Inc. S.E.H. has research collaborations with Merantix, Screen-Point, Lunit and Volpara. The remaining authors declare no competing interests.
: This work was supported by the Cancer Research UK (CRUK) grant [C543/A26884] and the NIHR Cambridge Biomedical Research Centre (BRC). F.J.G. is an NIHR Senior Investigator with funding from the Cambridge BRC. CRUK funds the PhD studentship for S.E.H. through an Early Detection programme grant [C543/A26884]. G.C.B. is funded by a studentship from GE Healthcare.